Given a blood sample and a suspected viral infection, which test directly looks for viral RNA?
A RT-qPCR after reverse transcription
B a chromosome karyotype
C a Western blot of host actin only
D an antibody ELISA alone
Answer: A. RT-qPCR after reverse transcription. RT-qPCR converts RNA into cDNA and amplifies the target while monitoring signal.
A sample contains a pathogen antigen, but the goal is to detect the patient’s antibodies against it. Which ELISA format is suitable?
A competitive PCR with no antibody
B indirect ELISA using immobilized antigen and an enzyme-linked secondary antibody
C direct ELISA using only a DNA primer
D sandwich ELISA with two primers
Answer: B. indirect ELISA using immobilized antigen and an enzyme-linked secondary antibody. Indirect ELISA can detect patient antibodies that bind immobilized antigen using a labeled secondary antibody.
A lab wants to detect a low-abundance protein in serum with high specificity. Which assay layout is often useful?
A sandwich ELISA with capture and detection antibodies
B DNA microarray without a protein probe
C standard PCR with no reverse transcription
D a karyotype
Answer: A. sandwich ELISA with capture and detection antibodies. A sandwich ELISA uses two binding reagents to capture and detect the protein.
A qPCR test for a target nucleic acid produces a much lower Ct than a comparable sample. Under validated assay conditions, this generally suggests
A no amplification occurred
B the target was a protein
C more starting target nucleic acid
D less starting target nucleic acid
Answer: C. more starting target nucleic acid. A lower Ct means the fluorescence threshold was reached in fewer cycles, usually indicating more starting template.
A genetic test detects a variant associated with altered drug metabolism. The relevant field is
A histology
B industrial fermentation
C pharmacogenomics
D micropropagation
Answer: C. pharmacogenomics. Pharmacogenomics connects genetic variants with drug response or metabolism.
A patient-derived T-cell product is collected, engineered, expanded, and returned to that patient. This approach is
A in vivo vaccination only
B autologous ex vivo cell therapy
C allogeneic embryo transfer
D hybridoma selection
Answer: B. autologous ex vivo cell therapy. Autologous approaches use the patient’s own cells, modified outside the body before infusion.
An immunoassay has high background signal in every well. Which step is most likely to reduce nonspecific binding?
A skip the incubation step
B improve blocking and washing
C remove the negative control
D increase the target concentration in all samples
Answer: B. improve blocking and washing. Blocking and washing reduce nonspecific binding and unbound detection reagent.
A patient has a positive antibody test but a negative pathogen-RNA test. Which interpretation is most careful?
A the sample must be contaminated
B the antibody result proves current infectiousness
C the tests measure different targets and timing or prior exposure may explain the result
D the RNA test always detects every infection
Answer: C. the tests measure different targets and timing or prior exposure may explain the result. Antibody and nucleic-acid tests measure different biological signals and can differ with timing, sensitivity, and infection stage.
A laboratory must determine whether a mutation is present in a specific gene. Which method can target that region for analysis?
A ELISA for total protein only
B PCR followed by sequencing or a variant-specific assay
C a cell count
D a vaccine challenge
Answer: B. PCR followed by sequencing or a variant-specific assay. PCR can amplify the target region for sequence analysis or variant-specific detection.
A test developer wants a positive result only when a specific protein is present. Which assay principle is central to ELISA?
A ribosomes reading the antigen
B cell fusion with a myeloma cell
C DNA polymerase copying the protein
D antibody binding to the target coupled to a measurable enzyme signal
Answer: D. antibody binding to the target coupled to a measurable enzyme signal. ELISA combines specific binding with enzyme-linked signal generation.
Which feature distinguishes RT-qPCR from a simple antibody test?
A it measures only antigenβantibody binding
B it identifies the patient’s entire phenotype
C it counts immune cells under a microscope
D it amplifies and monitors target nucleic acid
Answer: D. it amplifies and monitors target nucleic acid. RT-qPCR detects nucleic acid through reverse transcription and amplification with real-time monitoring.
A clinician needs to check whether a known fusion transcript is present. Which assay is a direct molecular approach?
A RT-PCR with primers spanning the transcript junction
B flow cytometry without a target antibody
C ELISA against total albumin
D a bacterial culture
Answer: A. RT-PCR with primers spanning the transcript junction. Primers spanning the fusion junction can amplify the specific transcript after reverse transcription.
Why might a mammalian cell line be chosen over E. coli for a complex therapeutic glycoprotein?
A bacteria cannot replicate plasmids
B mammalian cells remove every contaminant automatically
C E. coli cannot make any recombinant protein
D mammalian cells can provide eukaryotic folding and glycosylation
Answer: D. mammalian cells can provide eukaryotic folding and glycosylation. Mammalian cells support many eukaryotic post-translational processing steps needed by complex glycoproteins.
A patient is treated with CAR-T cells engineered from their own T cells. The engineered receptor helps the cells
A convert into monoclonal antibodies
B produce insulin in the pancreas
C recognize a selected target on diseased cells
D sequence every tumor mutation
Answer: C. recognize a selected target on diseased cells. The chimeric antigen receptor provides a target-recognition system for the engineered T cells.
A biosensor detects glucose using an enzyme and an electrical readout. In this design, the electrode acts as the
A transducer
B antibody
C gene promoter
D culture medium
Answer: A. transducer. The electrode converts the biochemical reaction into an electrical signal.
A lab compares gene-expression levels across hundreds of known genes in many samples. Which platform is designed for parallel hybridization?
A Western blot
B chromosome banding
C DNA microarray
D single-target ELISA
Answer: C. DNA microarray. Microarrays use many probes on one surface for parallel gene-expression or genotype measurements.
An NGS panel is ordered to examine many disease-associated genes at once. Its core advantage is
A massively parallel sequencing of many DNA fragments
B measurement of only one protein at a time
C guaranteed interpretation of every variant
D direct editing of each patient’s genome
Answer: A. massively parallel sequencing of many DNA fragments. Next-generation sequencing reads many DNA molecules in parallel, but clinical interpretation still requires evidence and context.
A genetic variant is classified as uncertain. What should be avoided?
A treating the uncertain result as a confirmed disease-causing variant
B providing appropriate genetic counseling
C reviewing family or functional evidence
D following validated interpretation standards
Answer: A. treating the uncertain result as a confirmed disease-causing variant. A variant of uncertain significance is not equivalent to a confirmed pathogenic result.
During gene therapy, cells are modified outside the body and tested before return. Which benefit does this workflow offer?
A it changes germ cells automatically
B it eliminates all immune risks
C some product checks can be done before administration
D it guarantees permanent cure
Answer: C. some product checks can be done before administration. Ex vivo processing allows characterization and quality checks before treated cells are administered.
A viral vector delivers a therapeutic gene but triggers an immune response. Which trade-off is being encountered?
A antibodies become DNA primers
B a vector cannot enter cells
C the gene is always destroyed in the nucleus
D efficient delivery can come with vector-related immunogenicity
Answer: D. efficient delivery can come with vector-related immunogenicity. Viral vectors can deliver genes effectively, but immune responses to vector components may limit use.
For a vaccine antigen produced in yeast, why is purification performed before formulation?
A to make the antigen replicate as a virus
B to convert protein into a chromosome
C to isolate the desired antigen and control impurities
D to eliminate the need for quality control
Answer: C. to isolate the desired antigen and control impurities. Purification separates the target antigen from host-cell components and process impurities.
A positive result is found in a no-template PCR control. What does this suggest?
A the assay is perfectly specific
B reverse transcription worked correctly
C the patient has the target sequence
D contamination of reagents or setup
Answer: D. contamination of reagents or setup. A no-template control should remain negative; amplification suggests contamination or nonspecific signal.
A clinical lab compares a new test with a validated reference method. What is the main purpose?
A increase the sample’s DNA concentration
B estimate performance such as sensitivity and specificity
C replace informed consent
D make a variant pathogenic
Answer: B. estimate performance such as sensitivity and specificity. Comparison with an appropriate reference supports evaluation of diagnostic performance.
A recombinant antibody binds a tumor-associated surface protein. What is the key first requirement for its intended targeting?
A expression of chlorophyll
B specific recognition of the target epitope
C ability to amplify DNA
D formation of a hybridoma in the patient
Answer: B. specific recognition of the target epitope. Target binding is central to a monoclonal antibody’s targeting mechanism.
A cell-based therapy is expanded before administration. Which measurement helps confirm the cells are alive at release?
A a pollen germination test
B blood pressure measurement
C DNA microarray only
D viability assay
Answer: D. viability assay. Viability assays estimate the proportion of living cells in a cell product.